Skip to content

Advertisement

  • Study protocol
  • Open Access
  • Open Peer Review

Digital Cognitive Behavioural Therapy for Insomnia versus sleep hygiene education: the impact of improved sleep on functional health, quality of life and psychological well-being. Study protocol for a randomised controlled trial

  • 1, 2Email author,
  • 1, 2,
  • 3, 2,
  • 4,
  • 5,
  • 6,
  • 7,
  • 2,
  • 2,
  • 2,
  • 8,
  • 1,
  • 8,
  • 9,
  • 10 and
  • 1
Trials201617:257

https://doi.org/10.1186/s13063-016-1364-7

©  Espie et al. 2016

  • Received: 12 December 2015
  • Accepted: 24 April 2016
  • Published:
Open Peer Review reports

Abstract

Background

Previous research has demonstrated that digital CBT (dCBT), delivered via the Internet, is a scalable and effective intervention for treating insomnia in otherwise healthy adults and leads to significant improvements in primary outcomes relating to sleep. The majority of people with insomnia, however, seek help because of the functional impact and daytime consequences of poor sleep, not because of sleep discontinuity per se. Although some secondary analyses suggest that dCBT may have wider health benefits, no adequately powered study has investigated these as a primary endpoint. This study specifically aims to investigate the impact of dCBT for insomnia upon health and well-being, and will investigate sleep-related changes as mediating factors.

Methods/design

We propose a pragmatic, parallel-group, randomised controlled trial of 1000 community participants meeting criteria for insomnia disorder. In the DIALS trial (Digital Insomnia therapy to Assist your Life as well as your Sleep), participants will be randomised to dCBT delivered using web and/or mobile channels (in addition to treatment as usual (TAU)) or to sleep hygiene education (SHE), comprising a website plus a downloadable booklet (in addition to TAU). Online assessments will take place at 0 (baseline), 4 (mid-treatment), 8 (post-treatment), and 24 (follow-up) weeks. At week 25 all participants allocated to SHE will be offered dCBT, at which point the controlled element of the trial will be complete. Naturalistic follow-up will be invited at weeks 36 and 48. Primary outcomes are functional health and well-being at 8 weeks. Secondary outcomes are mood, fatigue, sleepiness, cognitive function, productivity and social functioning. All main analyses will be carried out at the end of the final controlled follow-up assessments and will be based on the intention-to-treat principle. Further analyses will determine whether observed changes in functional health and well-being are mediated by changes in sleep. The trial is funded by Big Health Ltd.

Discussion

This study will be the first large-scale, specifically designed investigation of the health and well-being benefits of CBT for insomnia, and the first examination of the association between CBT-mediated sleep improvement and health status.

Trial registration

ISRCTN60530898.

Keywords

  • Insomnia
  • Sleep
  • CBT
  • Digital
  • Health
  • Function
  • well-being

Background

The importance of insomnia

Insomnia disorder comprises a complaint of poor sleep, with associated significant daytime effects, occurring at least 3 nights per week for at least 3 months [1]. Worldwide, epidemiologic studies report the prevalence of a chronic clinical insomnia disorder at 10 to 12 % [2–4]. Although prevalence is high, natural remission is low. In one study, 74 % of those with insomnia continued to have insomnia a year later and 46 % reported insomnia persisting for over 3 years [5]. Traditionally considered as ‘secondary’, subsumed as symptoms of other clinical diagnoses within mental health care, the recently revised Diagnostic and Statistical Manual of Mental Disorders, version 5 (DSM-5) outlines the ‘need for independent clinical attention of a sleep disorder’ (p. 1) [1]. This is supported by research demonstrating not only that rates of mental and physical health co-morbidity are high, but that pre-existing chronic insomnia is an independent risk factor for development of depression [6], cardiovascular disease [7] and type 2 diabetes [8, 9]. From the standpoint of public health and well-being, sleep appears to be a more important matter than has been hitherto recognised [10, 11].

The relationship between poor sleep, daytime functioning and quality of life

Typically, insomnia is associated with increased fatigue, impaired work productivity, reduced quality of life and relationship satisfaction, as well as increased ill-health [12–14]. Despite such evidence of poor functioning being attributed to poor sleep, and also being an essential diagnostic criterion for insomnia, there has been comparatively little research on quality of life. This is all the more surprising given that the perceived impact on personal functioning serves as an important driver of complaint and of help-seeking behavior rather than simply perceived sleep loss [15, 16]. In one large epidemiological study, four of the five most commonly cited reasons for seeking a sleep consultation with a health professional, were daytime consequences of fatigue, psychological distress, physical discomfort, and reduced work productivity [16]. Clinician reports of patient consultations, and cross-sectional and prospective questionnaire studies [17, 18] further demonstrate that individuals with insomnia complain of deficits in mood and cognitive abilities (concentration, memory, attention), coupled with elevated levels of anxiety, fatigue and physical pain/discomfort. Thus, once a threshold of noticeable effect on one’s life is reached, such individuals may feel motivated to seek medical advice.

Cognitive behavioural therapy (CBT) for insomnia

CBT, regarded as the treatment of first choice for persistent poor sleep [19–21] is a psychological treatment designed to break the patterns of maladaptive thinking and behaviour that serve to maintain insomnia. CBT comprises a range of techniques including a behavioural component (stimulus control, sleep restriction, relaxation) combined with a cognitive (managing sleep-related worries, the racing mind and intrusive thoughts) and an educational (sleep hygiene) component. Meta-analyses indicate that CBT has moderate to large and durable effects on sleep quality, sleep efficiency, sleep onset latency and wake time after sleep onset [22–24]. Moreover, approximately 60 % of those who receive CBT respond to treatment and 39 % achieve remission [25]. What is much less well-established is the effect that CBT may have upon the daytime symptom and functional health profile of people with insomnia. Logically, effective treatment should alleviate such impairments; and furthermore, based on the evidence that impaired sleep may be causally related to reduced quality of life domains (well-being and impaired daytime functional status), improving sleep should improve functioning. There is some preliminary evidence from secondary analyses that CBT may yield generalised benefits [26–29], and even some primary data in small samples that CBT for insomnia may reduce depressive or anxiety symptoms [30, 31], but an adequately powered, definitive trial examining functional health status and well-being is long overdue.

The current study

This study seeks to ascertain the impact of improved sleep on three key areas of quality of life: functional health status, patient-generated (sleep-related) quality of life impairment and psychological well-being. Over the past 5 years, self-help CBT delivered via the Internet has been introduced, not least because of the importance of widening access to effective psychological therapy. Several randomised controlled trials (RCTs) have evaluated digital CBT (dCBT) applications; each of which has found moderate to large improvements in insomnia symptoms relative to waitlist groups [32–34]. Only one programme, however, has been tested versus a placebo intervention, demonstrating significant and sustained improvements in sleep continuity; for example, sleep diary-assessed sleep efficiency, sleep onset latency and wake time after sleep onset, and self-reported global sleep quality [34]. It is this dCBT intervention that will be used in the present study. Data from the programme show that more than 80 % of participants complete the course within 8 weeks.

The primary hypotheses for the trial are that, compared to sleep hygiene education (SHE):
  1. 1.

    The dCBT intervention will be associated with improved functional health status by the end of treatment (8 weeks)

     
  2. 2.

    The dCBT intervention will improve positive psychological well-being by the end of treatment (8 weeks)

     
  3. 3.

    The dCBT intervention will be associated with reduced patient-generated sleep-related quality of life impairment (8 weeks)

     
  4. 4.

    The effect of dCBT on outcomes (8 weeks) will be mediated by sleep status during the treatment phase (4 weeks)

     
The secondary hypotheses are that, compared to SHE:
  1. 1.

    The dCBT intervention will be associated with reduced symptoms of negative mood, fatigue and relationship/social dysfunction by the end of treatment (8 weeks)

     
  2. 2.

    The dCBT intervention will be associated with reduced problems with sleepiness, cognitive impairment and productivity by the end of treatment (8 weeks)

     
  3. 3.

    Improvements will be maintained at follow-up (24, 36, 48 weeks)

     
  4. 4.

    The effect of dCBT on longer-term outcomes (24, 36, 48 weeks) will be mediated by sleep status during and upon completion of the treatment phase (4, 8 weeks)

     

Methods/design

Research design

The study is a parallel-group, superiority, RCT of dCBT (+ treatment as usual, TAU) versus SHE (+TAU). The trial design is summarised in Fig. 1. The study will be carried out completely online. Participants will access the screening assessment, participant information statement, informed consent form, allocation to condition and intervention, and baseline and follow-up assessments via web or mobile platforms (see also Additional files 1 and 2). Participants will be able to print a copy of the participant information statement and will have the opportunity to contact the researchers via phone or email before consenting. The study has received ethical approval from the University of Oxford Medical Sciences Inter-Divisional Ethics Committee (ref MS-IDREC-C2-2015-024) and is registered at ISCRTN (ISRCTN60530898).
Fig. 1
Fig. 1

Summary of the trial design for the Digital Insomnia therapy to Assist your Life as well as your Sleep (DIALS) study. SCI Sleep Condition Indicator, dCBT digital cognitive behavioural therapy, SHE sleep hygiene education

Participants

We will recruit 1000 community participants. Our inclusion criteria comprise: (1) a positive screen for probable DSM-5 insomnia disorder, (2) a test score of ≤ 16 on the Sleep Condition Indicator (SCI) [35], (3) being aged 18 or older (no upper age limit), (4) having reliable Internet access at home or at work, and (5) being able to read and understand English. We will screen for co-morbid conditions and medication use at baseline but exclude only those people whose health may be considered to be unstable such as significant current symptoms of (a) an additional sleep disorder (e.g. excessively sleepy and possible obstructive sleep apnoea), (b) psychosis or mania, (c) serious physical health concerns necessitating surgery or with a prognosis less than 6 months, (d) those undergoing a psychological treatment programme for insomnia with a health professional, and (e) habitual night shift, evening, or rotating shift-workers. Information covering (a) to (e) will be gathered using online self-report questions, there will be no medical examinations or access to medical records. We will not omit participants who take medication for sleep problems, or for any other physical or mental health problems providing they report their health to be stable. The study will recruit through several channels. These may include online, print and broadcast media announcements or advertisements and the use of contact lists where adults who have volunteered to be involved in research will be re-contacted (See Additional file 3). For example, following completion of open access sleep surveys such as the Great British Sleep Survey (GBSS: www.greatbritishsleepsurvey.com or World Sleep Survey, WSS: www.worldsleepsurvey.com, which generate data on tens of thousands of respondents). Potential participants will also be alerted to the study by information placed on the Sleepio® website (www.sleepio.com) and on the Sleepio® App site (which generate data on hundreds of thousands of respondents). Participants will not receive reimbursement for their participation, but will be provided with access to the dCBT programme free of charge, regardless of allocation to experimental condition. Informed consent will be obtained from all participants.

Randomisation and allocation concealment

This study will use simple randomisation with an allocation ratio of 1:1, as recommended for large clinical trials [36]. It will be carried out by the automated online system. Hence the research team will be unable to influence randomisation, and will have no access to future allocations.

Blinding

This is a single-blind trial. Self-report assessments will be completed online and hence the research team will be blind to outcomes during the trial. Participants will be informed of their randomisation outcome by an automatic email, and so they will not be blind to treatment allocation. The research team will have limited contact with research participants and will be unable to bias the allocation or influence the assessments. If participants do contact the team and reveal the allocation, the assessments will remain blinded. Statistical analyses will be conducted by an independent researcher (RE; University of Manchester) who will have access to all data.

Assessment points

Assessments will take place at weeks 0 (baseline), 4 (mid-treatment), 8 (post-treatment), and 24 (follow-up). In consideration of ethical matters, at week 25 all participants in the control group will be offered dCBT to help with their sleep problems, and so at that point the controlled element of the trial will be complete. Thereafter, there will be a naturalistic follow-up. All participants will be invited to complete further assessments at weeks 36 and 48.

Planned intervention

Digital cognitive behavioural therapy will be delivered using the Sleepio® programme [34] (www.sleepio.com and associated Sleepio® App). The programme is fully automated and its underlying algorithms feed the delivery of information, support, and advice in a personally tailored manner. Delivery is structured into six sessions, lasting an average of 20 minutes each. Certain tools (such as sleep diaries and relaxation audios) can also be accessed using the web browser of any smartphone. All of the six core sessions, sleep diaries, relaxation audios, and the scheduling tool can also be accessed using an iOS App, but this is only an option for participants who have an iPhone®. The treatment content is based on CBT for insomnia manuals [26–28] and includes a behavioural component (sleep restriction, stimulus control, and relaxation), a cognitive component (paradoxical intention, cognitive restructuring, mindfulness, positive imagery, and putting the day to rest) and an educational component (psycho-education and sleep hygiene).

The programme is highly interactive, and content is presented by an animated virtual therapist. Participants make a time for the session and are prompted via email and/or short text message (SMS) if they do not ‘attend’. Participants complete daily sleep diary information throughout the intervention, which is used by the programme to provide tailored, personalised help. Participants receive an email and/or SMS reminder each morning to prompt them to fill in their sleep diary. In addition, participants complete a short questionnaire at the beginning of therapy to set treatment goals. Throughout the course of therapy, participants have access to a moderated online community and an online library of information about sleep. Participants can view their online case file, which includes four sections: a progress review, a reminder of strategies to try out between sessions, an agreed sleep schedule, and a list of further reading. The system provides online analytics, which can be used to monitor adherence by assessing how many sessions were completed and the number of weeks to complete the course. All information gathered for the programme will be stored in encrypted form on secure servers. Passwords are stored in encrypted form and all sensitive traffic is transmitted securely via SSL by default. Participants will have access to the intervention for up to 12 weeks. Digital CBT will in effect be dCBT + TAU because there will be no requirement for participants to alter their usual care in any way. Physicians, for example, will be free to offer appointments, to prescribe, and to maintain/discontinue prescriptions as they see fit.

Sleep hygiene education (SHE) has been selected for the control arm because this is what people with insomnia are offered most typically in routine care. To ensure consistency of approach and content, SHE will be delivered on a dedicated website where materials can be viewed and downloaded. SHE will be based on recognised sleep hygiene advice [37–39] and will comprise behavioural advice concerning both lifestyle factors and environmental factors associated with sleep and sleeplessness. The latter in particular will focus on creating the optimal bedroom environment for good sleep. The content of SHE will cover the importance of limiting caffeine, nicotine, and alcohol and of carefully managing diet and exercise (lifestyle), as well as limiting noise and light, managing room temperature and body temperature, and improving air quality and bed comfort (environment). SHE will in effect be SHE + TAU because again there will be no requirement for the usual care of participants to be altered in any way.

Outcome measures

Participants will be prompted by email to complete the assessments in an online, secure environment (www.surveygizmo.eu). The order of the assessments will be consistent across all participants and all time-points. If participants do not complete measures within 2 days they will receive further email reminders. The full battery of questionnaires amounts to around 100 items in total, and takes 20–25 minutes to complete. We have evidence from a recently completed protocol that data on such measures can be successfully collected online [40]. Demographic and descriptive clinical data will be gathered at baseline only. Measurements to permit health economic evaluation will form part of the descriptive demographic data, with some aspects audited at each assessment point (e.g. medication use, visits to health professionals, other health care utilisation). Descriptive data on health behaviours such as smoking and alcohol use will also be reported.

The co-primary measures that relate to functional health and well-being will be the Patient Reported Outcome Measurement Information System: Global Health scale [41] (PROMIS-10), the Warwick-Edinburgh Mental Well-being Scale [42] (WEMWBS) and the Glasgow Sleep Impact Index [43] (GSII). The PROMIS-10 is a reliable (α ≥ .92) but brief (10 items), generic measure that has proven to be very useful in measuring outcomes in clinical trials (http://www.nihpromis.org/science/). It can also be used to estimate cost-utility using QALYs (quality-adjusted life-years) [44, 45]. The WEMWBS is a short (14 items) and psychometrically robust measure (α ≥. 91) of mental well-being and is included because it focuses entirely on positive aspects of functional mental health. A previous pilot trial suggests the WEMWBS is sensitive to changes after CBT for insomnia [46]. The GSII is a patient-reported outcome (PRO) measure that asks patients to individually generate, and then assess, three domains of sleep-related impairment unique to their own individual context. Its strength is ecological validity and the GSII has been shown to be sensitive to change following CBT [43]. This combination of PRO, generic functional health status, and positive mental state (rather than symptom reduction) matches our intention to evaluate the impact of dCBT upon quality of life domains.

Secondary outcomes relate to specific measurement of the six areas of daytime consequence that are associated with the clinical diagnosis of insomnia disorder [1, 14, 47]. These are mood (Patient Health Questionnaire (PHQ-9: 9 items [48]) and Generalised Anxiety Disorder (GAD-7: 7 items [49])); energy (Flinders Fatigue Scale (FFS: 7 items [50]); relationship satisfaction (Relationship Assessment Scale (RAS: 7 items [51]); cognitive functioning (Cognitive Failures Questionnaire (CFS: 25 items [52])]; work performance and satisfaction (Work Productivity and Activity Impairment questionnaire: Specific Health Problem (WPAI:SHP: 6 items [53]), 1 item on job satisfaction [54]); and sleepiness (Epworth Sleepiness Scale (ESS: 8 items [55]). As an exploratory measure, participants will also complete 1 item about their general life satisfaction [56].

In order to appraise the mediating effects of sleep improvement per se we will use the SCI [35] and estimates of sleep diary parameters [57]. The SCI is an internally consistent (α = .86) measure with a clinical cut off that can correctly identify 89 % of those with probable DSM-5 insomnia disorder. The SCI and sleep diary variables have proven to be sensitive to change following dCBT [34].

In addition to these formal assessments the web/mobile platform will provide online analytics for the dCBT group. These can be used, for example, to measure the process of change (sleep diary) and to monitor how many sessions were completed and the number of weeks to complete the course. These will be used in exploratory analyses. We will also gather information on the demographics of the sample, employment, work satisfaction and economic outcomes, their health characteristics, and their use of clinical services during the period of their trial participation.

Assessment of safety

The likelihood of serious adverse events occurring during this trial is low since dCBT for insomnia has not been reported to cause them. The intervention offered in the trial has previously been tested in a RCT testing change in insomnia and no adverse outcomes were reported [29, 34]. However, studies have shown that daytime sleepiness and vigilance impairment may increase during sleep restriction therapy (SRT) (one component of CBT-I), owing to restricted sleep opportunity [58]. We will record the occurrence of any serious adverse events in trial participants, defined as: (1) all deaths, (2) suicide attempts, (3) serious violent incidents, (4) admissions to secure units, and (5) formal complaints about the online intervention. Owing to the online nature of the assessments and intervention, it is unlikely that the research team will become aware of all such events. At the end of treatment we will also ask participants to complete an adapted version of a previously employed adverse effects measure [59] to assess differential rates of self-reported adverse effects.

Sample size calculation

Our planned primary intention-to-treat analyses will compare dCBT + TAU versus SHE + TAU for each of the three primary outcomes separately. Assuming a significance level of 1.667 % (adjusted from 5 % because of having three primary outcomes) and a power of 90 %, to detect a standardised effect size of 0.25 we require a minimum of 433 participants in each of the groups in the analysis. Accounting for a conservative dropout rate of 13 %, we will recruit 500 participants in each treatment group, or 1000 participants in all. This sample size will have more than 80 % power to detect a large-sized indirect effect through the sleep mediator (proportion mediated approximately 75 %) for each between-group comparison. We believe that a sample of this size is feasible to recruit for two reasons. First, online/mobile interventions are much more accessible than in person interventions; and second, published research using dCBT has already shown that large samples may be recruited over comparatively short recruitment periods.

Statistical analysis

All analyses will be carried out using Stata [60]. In accordance with Consolidated Standards of Reporting Trials (CONSORT) guidelines, we will report all participant flow. Descriptive statistics of recruitment, dropout and completeness of interventions will be provided.

The main efficacy analysis will be via intention-to-treat including all participants, with no planned interim analysis for efficacy or futility. Baseline characteristics will be presented by randomised group without formal statistical tests. We will test the primary hypothesis for between-group change in the primary outcomes at 8 weeks using analysis of covariance with baseline outcome measure and treatment assignment as fixed effects, and apply standard regression diagnostics. The analysis will use statistical techniques for handling missing outcome data under a missing-at-random assumption. The secondary outcomes will be analysed using an analogous method, as will subsequent measures of the primary outcomes at 24 weeks. Analysis of all treatment effects will be undertaken after all 24-week outcome measures are completed.

We will use modern causal inference methods to investigate the mediation hypothesis [61]. If the efficacy analysis shows significant between-group differences in the SCI at 4 and 8 weeks, then we will use parametric regression models to test for the indirect effect of SCI on outcomes, and the residual direct effect of treatment on outcomes at 8 and 24 weeks respectively. Since all the measures are continuous, the indirect effects are calculated by multiplying relevant pathways and bootstrapping is used to produce valid standard errors for the indirect effects. All analyses will adjust for baseline measures of the SCI, outcomes and putative measured confounders. Mediation analyses are potentially biased by measurement error in mediators and hidden confounding between mediators and outcomes and we will investigate the sensitivity of the estimates to these problems.

Dissemination policy

Results from this study will be published in peer-reviewed scientific papers, and presented at major national and international clinical scientific meetings. Findings, wherever possible, will be made accessible online, dependent upon journal policies.

Discussion

It is already well-established that CBT is the treatment of first choice for people with chronic insomnia, and that sleep-related outcomes, whether on index measures of insomnia or on derivations from sleep diaries, show sustained improvement [19–21]. A recent definitive placebo-controlled RCT has also demonstrated that dCBT yields effect sizes that mirror conventionally delivered face-to-face therapy [34]. What is yet to be established is whether or not CBT for insomnia is causally associated with changes in functional health, quality of life and psychological well-being. This is crucial for two reasons. First, a diagnosis of insomnia disorder cannot be made unless there are clear attributed daytime consequences of night-time poor sleep; and second, it is the degradation of people’s lived experience and quality of life that often leads to clinical complaint and help-seeking behaviour. An investigation of such as primary outcomes is long overdue. This study will be the first specifically designed investigation of the health and well-being benefits of CBT for insomnia, and the first large-scale test of the relationship between CBT-mediated sleep improvement and health status. The results can be expected to influence care provision for the 10–12 % of the adult population who have persistent insomnia problems. In particular, the results may indicate that sleep is a novel therapeutic target in relation to generalised health benefit and improved quality of life. Moreover, because we will be using a dCBT approach, a scalable solution to insomnia may be demonstrated as both viable and effective.

Trial status

Recruitment will begin in December 2015. It is anticipated that recruitment will be complete in Summer 2016. Therefore, trial results will become available in late 2016.

Abbreviations

CBT, cognitive behavioural therapy; CFS, Cognitive Failures Questionnaire; CI, Chief Investigator; dCBT, digital cognitive behavioural therapy; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, 5th edition; ESS, Epworth Sleepiness Scale; FFS, Flinders Fatigue Scale; GAD-7, Generalised Anxiety Disorder assessment (7-item version); GBSS, Great British Sleep Survey; GSII, Glasgow Sleep Impairment Index; PHQ-9, Patient Health Questionnaire – 9- item version; PROMIS-10, Patient Reported Outcomes Measurement Information System, Global Health scale (10 items); QALY, quality-adjusted life-years; RAS, Relationship Assessment Scale; RCT, randomised controlled trial; SCI, Sleep Condition Indicator; SCNi, Sleep and Circadian Neuroscience Institute; SHE, sleep hygiene education; TAU, treatment as usual; WEMWBS, Warwick- Edinburgh Mental Well-being Scale; WPAI,SHP, Work Productivity and Activity Impairment questionnaire, Specific Health Problem; WSS, World Sleep Survey

Declarations

Acknowledgement

The study is funded by Big Health Ltd. (Sleepio​®).

Authors’ contributions

CAE is the chief investigator, conceived of the study, contributed to the design, and drafted the manuscript. AIL is the trial co-ordinator, helped to draft the manuscript and is responsible for the computer programming that carries out the screening, assessments, and links to the digital intervention. JC contributed to the design, and helped to draft the manuscript. CLD contributed to the design, and helped to draft the manuscript. ANS contributed to the design, and helped to draft the manuscript. JCO contributed to the design, and helped to draft the manuscript. CG contributed to the design, and helped to draft the manuscript. SB contributed to the design and is responsible for the digital therapy programme. PH contributed to the design. MN helped to draft the manuscript, and will assist with the computer programming that carries out the screening, assessments, and links to the digital intervention. BS contributed to the design, and helped to draft the manuscript. RF contributed to the design of the trial. DF contributed to the design of the trial. JC-F contributed to the design, and helped to draft the manuscript. RE contributed to the design, is responsible for the main statistical outcome analysis and is responsible for the statistical mediation analysis. SDK conceived of the study, contributed to the design, and helped to draft the manuscript. All authors approved the final manuscript.

Competing interests

CAE is the co-founder and Clinical and Scientific Director of the CBT for insomnia programme (Big Health Ltd., Sleepio®). Peter Hames is the co-founder/CEO, and SB is the Head of UK Operations for the programme. AIL holds a position at Oxford that is funded by the programme. JC provides clinical advice and support to the programme, BS provides monthly support for an online discussion forum run by the programme and SDK and JCO provide consultancy support. MN has worked as an intern for the programme. The programme is being provided to all participants at no cost. No other investigators have conflicts of interest. The study will be conducted by the University of Oxford, Sleep and Circadian Neuroscience Institute. The University of Oxford has a Memorandum of Understanding with Big Health Ltd. (Sleepio​®) for the conduct of joint research.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neurosciences, University of Oxford, Sir William Dunn School of Pathology, Oxford, UK
(2)
Big Health Ltd., London, UK
(3)
Division of Psychology and Language Sciences, Faculty of Brain Sciences, University College London, London, UK
(4)
Department of Sleep Disorders and Research Center, Henry Ford Health System, Detroit, MI, USA
(5)
School of Health and Social Care, University of Lincoln, Lincoln, UK
(6)
Rush University Medical Center, Chicago, IL, USA
(7)
CIRUS Centre for Integrated Research and Understanding of Sleep, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia
(8)
Sleep and Circadian Neuroscience Institute, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
(9)
The London School of Economics and Political Science, London, UK
(10)
Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

References

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013.Google Scholar
  2. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002;6:97–111.View ArticlePubMedGoogle Scholar
  3. Lichstein KL, Durrence HH, Reidel BW, et al. The epidemiology of sleep: age, gender and ethnicity. Mahwah: Lawrence Erlbaum Associates; 2004.Google Scholar
  4. Morphy H, Dunn KM, Lewis M, et al. Epidemiology of insomnia: a longitudinal study in a UK Population. Sleep. 2007;30(3):274–80.PubMedGoogle Scholar
  5. Morin CM, Belanger L, LeBlanc M, et al. The natural history of insomnia: a population-based 3-year longitudinal study. Arch Intern Med. 2009;169:447–53.View ArticlePubMedGoogle Scholar
  6. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011;135:10–9.View ArticlePubMedGoogle Scholar
  7. Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32:491–7.PubMedPubMed CentralGoogle Scholar
  8. Vgontzas AN, Liao D, Pejovic S, Calhoun S, Karataraki M, Bixler EO. Insomnia with objective short sleep duration is associated with type 2 diabetes: a population-based study. Diabetes Care. 2009;32:1980–5.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of type 2 diabetes. A systematic review and meta-analysis. Diabetes Care. 2010;33(2):414–20.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Luyster FS, Strollo PJ, Zee PC, on behalf of the Boards of Directors of the American Academy of Sleep Medicine and the Sleep Research Society JK. Sleep: a health imperative. Sleep. 2012;35(6):727–34.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Buysse DJ. Sleep health: can we define it? Does it matter? Sleep. 2014;37(1):9–17.PubMedPubMed CentralGoogle Scholar
  12. Roth T, Ancoli-Israel S. Daytime consequences of insomnia in the United States: results of the 1991 National Sleep Foundation Survey II. Sleep. 1999;22 Suppl 2:S354–63.PubMedGoogle Scholar
  13. Kyle SD, Morgan K, Espie C. Insomnia and health-related quality of life. Sleep Med Rev. 2010;14:69–82.View ArticlePubMedGoogle Scholar
  14. Espie CA, Kyle SD, Hames P, et al. The daytime impact of DSM-5 insomnia disorder: comparative analysis of insomnia subtypes from the Great British Sleep Survey (n = 11,129). J Clin Psychiatry. 2012;73:e1478–84.View ArticlePubMedGoogle Scholar
  15. Stepanski E, Koshorek G, Zorick F, Glinn M, Roehrs T, Roth T. Characteristics of individuals who do or do not seek treatment for chronic insomnia. Psychosomatics. 1989;30:421–7.View ArticlePubMedGoogle Scholar
  16. Morin CM, LeBlanc M, Daley M, Gregoire JP, Mérette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. Sleep Med. 2007;7(2):123–30.View ArticleGoogle Scholar
  17. Buysse DJ, Thompson W, Scott J, Franzen PL, Germain A, Hall M, et al. Daytime symptoms in primary insomnia: a prospective analysis using ecological momentary assessment. Sleep Med. 2007;8(3):198–208.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Levitt H, Wood A, Moul DE, Hall M, Germain A, Kupfer DJ, et al. A pilot study of subjective daytime alertness and mood in primary insomnia participants using ecological momentary assessment. Behav Sleep Med. 2004;2(2):113–31.View ArticlePubMedGoogle Scholar
  19. National Institute for Clinical Excellence (NICE). Managing long-term insomnia (>4 weeks). 2014. http://cks.nice.org.uk/insomnia#!scenario:1. Accessed Dec 2015.
  20. NIH. State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults. NIH Consens Sci Statements. 2005;22:1–30.Google Scholar
  21. Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–600.View ArticlePubMedGoogle Scholar
  22. Trauer JM, Qian MY, Doyle JS, Rajaratnam SMW, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med. 2015;163:191–204.View ArticlePubMedGoogle Scholar
  23. Wu JQ, Appleman ER, Salazar RD, Ong JC. Cognitive behavioral therapy for insomnia comorbid with psychiatric and medical conditions: a meta-analysis. JAMA Intern Med. 2015;175:1461–72.View ArticlePubMedGoogle Scholar
  24. Mitchell MD, Gehrman P, Perlis M, Umscheid CA. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012;13(1):40.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Morin CM, Vallières A, Guay B, Ivers H, Savard J, Mérette C, et al. Cognitive-behavior therapy, singly and combined with medication, for persistent insomnia: acute and maintenance therapeutic effects. JAMA. 2009;301(19):2005–15.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Espie CA, Inglis SJ, Tessier S, Harvey L. The clinical effectiveness of cognitive behaviour therapy for chronic insomnia: implementation and evaluation of a sleep clinic in general medical practice. Behav Res Ther. 2001;39(1):45–60.View ArticlePubMedGoogle Scholar
  27. Espie CA, MacMahon KM, Kelly H, et al. Randomized clinical effectiveness trial of nurse-administered small group cognitive behaviour therapy for persistent insomnia in general practice. Sleep. 2007;30:574–84.PubMedGoogle Scholar
  28. Espie CA, Fleming L, Cassidy J, et al. Randomized controlled clinical effectiveness trial of cognitive behaviour therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol. 2008;26:4651–8.View ArticlePubMedGoogle Scholar
  29. Espie CA, Kyle SD, Miller CB, Ong J, Hames P, Fleming L. Attribution, cognition and psychopathology in persistent insomnia disorder: outcome and mediation analysis from a randomized placebo-controlled trial of online cognitive behavioural therapy. Sleep Med. 2014;15(8):913–7.View ArticlePubMedGoogle Scholar
  30. Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, Kalista T. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep. 2008;31:489–95.PubMedPubMed CentralGoogle Scholar
  31. Pillai V, Anderson JR, Cheng P, Bazan L, Bostock S, Espie CA, et al. The anxiolytic effects of cognitive behavior therapy for insomnia: preliminary results from a web-delivered protocol. J Sleep Med Disord. 2015;2(2):1017.Google Scholar
  32. Ritterband LM, Thorndike FP, Gonder-Frederick GA, et al. Efficacy of an Internet-based behavioral intervention for adults with insomnia. Arch Gen Psychiatry. 2009;66:692–8.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Vincent N, Lewycky S. Logging on for better sleep: RCT of the effectiveness of online treatment for insomnia. Sleep. 2009;32:807–15.PubMedPubMed CentralGoogle Scholar
  34. Espie CA, Kyle SD, Williams C, et al. A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep. 2012;35(6):769–81.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Espie CA, Kyle SD, Hames P, Gardani M, Fleming L, Cape J. The Sleep Condition Indicator: a clinical screening tool to evaluate insomnia disorder. BMJ Open. 2014;4(3), e004183.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Hewitt CE, Torgerson DJ. Research methods: is restricted randomisation necessary? Br Med J. 2006;332(7556):1506.View ArticleGoogle Scholar
  37. American Academy of Sleep Medicine. How to sleep better. Darien: AASM; 2012.Google Scholar
  38. Espie CA. Overcoming insomnia and sleep problems: a self-help guide using cognitive behavioral techniques (chapter on sleep hygiene). London: Constable & Robinson; 2006.Google Scholar
  39. National Sleep Foundation. Sleep tools. http://sleepfoundation.org/sleep-tools-tips/healthy-sleep-tips, downloaded 14 May 2015.
  40. Freeman D, Sheaves B, Goodwin GM, et al. Effects of cognitive behavioural therapy for insomnia on the mental health of university students: study protocol for a randomized controlled trial. Trials. 2015;16:236.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Hays RD, Bjorner J, Revicki RA, Spritzer KL, Cella D. Development of physical and mental health summary scores from the Patient Reported Outcomes Measurement Information System (PROMIS) global items. Qual Life Res. 2009;18(7):873–80.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Tennant T, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-Edinburgh Mental Well-being Scale (WEMWBS): development and UK validation. Health Qual Life Outcomes. 2007;5(1):63.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Kyle SD, Crawford MR, Morgan K, Spiegelhalder K, Clark AA, Espie CA. The Glasgow Sleep Impact Index (GSII): a novel patient-centred measure for assessing sleep-related quality of life impairment in insomnia disorder. Sleep Med. 2013;14(6):493–501.View ArticlePubMedGoogle Scholar
  44. Revicki DA, Kawata A, Harnam N, et al. Predicting EuroQol (EQ-5D) scores from the Patient Reported Outcomes Measurement Information System (PROMIS) global items and domain item banks in a United States representative sample. United Bio-Source Corp. Working Paper, November 2008Google Scholar
  45. Lipscomb J, Drummond M, Fryback D, Gold M, Revicki D. Retaining, and enhancing, the QALY. Value Health. 2009;12(1):S18–26.View ArticlePubMedGoogle Scholar
  46. Freeman D, Waite F, Startup H, Myers E, Lister R, McInerney J, et al. Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial. Lancet Psychiatry. 2015;2:975–83.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Miller CB, Kyle SD, Marshall NS, Espie CA. Ecological momentary assessment of daytime symptoms during sleep restriction therapy for insomnia. J Sleep Res. 2013;22(3):266–72.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Kroenke K, Spitzer RL, Williams JBW, Löwe B. The Patient Health Questionnaire somatic, anxiety and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32:345–59.View ArticlePubMedGoogle Scholar
  49. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;16(10):1092–7.View ArticleGoogle Scholar
  50. Gradisar M, Lack L, Richards H, Harris J, Gallasch J, Boundy M, et al. The Flinders Fatigue Scale: preliminary psychometric properties and clinical sensitivity of a new scale for measuring daytime fatigue associated with insomnia. J Clin Sleep Med. 2007;3(7):722.PubMedPubMed CentralGoogle Scholar
  51. Hendrick SS, Dicke A, Hendrick C. The Relationship Assessment Scale. J Soc Pers Relat. 1998;15(1):137–42.View ArticleGoogle Scholar
  52. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982;21:1–16.View ArticlePubMedGoogle Scholar
  53. Reilly MC, Zbrozek AS, Dukes E. The validity and reproducibility of a work productivity and activity impairment measure. Pharmacoeconomics. 1993;4(5):353–65.View ArticlePubMedGoogle Scholar
  54. Dolbier CL, Webster JA, McCalister KT, Mallon MW, Steinhardt MA. Reliability and validity of a single-item measure of job satisfaction. Am J Health Promot. 2005;19(3):194–8.View ArticlePubMedGoogle Scholar
  55. Johns MW. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep. 1997;14(6):540–5.Google Scholar
  56. Cheung F, Lucas RE. Assessing the validity of single-item life satisfaction measures: results from three large samples. Qual Life Res. 2014;23(10):2809–18.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein KL, et al. The consensus sleep diary: standardizing prospective sleep self-monitoring. Sleep. 2012;35(2):287.PubMedPubMed CentralGoogle Scholar
  58. Kyle SD, Miller CB, Rogers Z, Siriwardena AN, MacMahon KM, Espie CA. Sleep restriction therapy for insomnia is associated with reduced objective total sleep time, increased daytime somnolence, and objectively impaired vigilance: implications for the clinical management of insomnia disorder. Sleep. 2014;37(2):229–37.PubMedPubMed CentralGoogle Scholar
  59. Kyle SD, Morgan K, Spiegelhalder K, Espie CA. No pain, no gain: an exploratory within-subjects mixed-methods evaluation of the patient experience of sleep restriction therapy (SRT) for insomnia. Sleep Med. 2011;18(8):735–47.View ArticleGoogle Scholar
  60. StataCorp. Stata Statistical Software: Release 14. College Station: StataCorp LP; 2015.Google Scholar
  61. Emsley R, Dunn G, White IR. Mediation and moderation of treatment effects in randomised controlled trials of complex interventions. Stat Methods Med Res. 2010;19(3):237–70.View ArticlePubMedGoogle Scholar

Copyright

© Espie et al. 2016

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement

Trials

ISSN: 1745-6215